Pathology: es-BC - TNBC - NA - all population; es-BC - TNBC - NA - PDL1 positive;
es-BC - TNBC - NA - all population | es-BC - TNBC - NA - PDL1 positive | ||
IMpassion-031 (all population), 2020 | IMpassion-031 (PDL1>1%), 2020 | ||
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | 2 | T1 | T1 |
placebo plus SoC | 0 | T0 | T0 |